Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders, 14104-14106 [2017-05256]
Download as PDF
14104
Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices
by the Department of Transportation,
and, based on comments to the
proposed rule finalized on December 17,
2013, as discussed above, the data are
no longer used by trucking associations.
Insurance companies, consultants, law
firms, academia, trade publications and
others may use the data to assess
industry growth and its impact on the
economy, to identify industry changes
that may affect national transportation,
and to monitor company financial
stability. The Bureau of Economic
Analysis (BEA) of the U.S. Department
of Commerce uses the data to inform the
national annual input-output and Gross
Domestic Product (GDP) estimates. BEA
uses the data to prepare estimates of
industry output and provide details on
inputs to supplement the information
on motor carriers of passengers
collected by the U.S. Census Bureau.
Title: Annual Report of Class I Motor
Carriers of Passengers.
OMB Control Number: 2126–0031.
Type of Request: Extension of a
currently approved information
collection.
Respondents: Motor Carriers.
Estimated Number of Respondents:
408.
Estimated Time per Response: 18
minutes.
Expiration Date: April 30, 2017.
Frequency of Response: Annually.
Estimated Total Annual Burden: 122
hours (408 responses × 18 minutes per
response/60 = 122.4 rounded to 122).
mstockstill on DSK3G9T082PROD with NOTICES
PUBLIC COMMENTS INVITED: You are asked
to comment on any aspect of this
information collection, including: (1)
Whether the proposed collection is
necessary for the performance of
FMCSA’s functions; (2) the accuracy of
the estimated burden; (3) ways for
FMCSA to enhance the quality,
usefulness, and clarity of the collected
information; and (4) ways that the
burden could be minimized without
reducing the quality of the collected
information. The agency will summarize
or include your comments in the request
for OMB’s clearance of this information
collection.
Issued under the authority of 49 CFR 1.87
on: March 9, 2017.
Kelly Regal,
Associate Administrator for Office of
Research and Information Technology.
[FR Doc. 2017–05258 Filed 3–15–17; 8:45 am]
BILLING CODE 4910–EX–P
VerDate Sep<11>2014
17:12 Mar 15, 2017
Jkt 241001
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2016–0315]
Qualification of Drivers; Exemption
Applications; Epilepsy and Seizure
Disorders
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption; request for comments.
AGENCY:
FMCSA announces receipt of
applications from eight individuals for
an exemption from the prohibition in
the Federal Motor Carrier Safety
Regulations (FMCSRs) against persons
with a clinical diagnosis of epilepsy or
any other condition that is likely to
cause a loss of consciousness or any loss
of ability to control a commercial motor
vehicle (CMV) to drive in interstate
commerce. If granted, the exemptions
would enable these individuals who
have had one or more seizures and are
taking anti-seizure medication to
operate CMVs in interstate commerce.
DATES: Comments must be received on
or before April 17, 2017.
ADDRESSES: You may submit comments
bearing the Federal Docket Management
System (FDMS) Docket No. FMCSA–
2016–0315 using any of the following
methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov. Follow the
online instructions for submitting
comments.
• Mail: Docket Management Facility;
U.S. Department of Transportation, 1200
New Jersey Avenue SE., West Building
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery: West Building
Ground Floor, Room W12–140, 1200
New Jersey Avenue SE., Washington,
DC, between 9 a.m. and 5 p.m., e.t.,
Monday through Friday, except Federal
Holidays.
• Fax: 1–202–493–2251.
Instructions: Each submission must
include the Agency name and the
docket number(s) for this notice. Note
that all comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. Please
see the Privacy Act heading below for
further information.
Docket: For access to the docket to
read background documents or
comments, go to https://
www.regulations.gov at any time or
Room W12–140 on the ground level of
the West Building, 1200 New Jersey
SUMMARY:
PO 00000
Frm 00132
Fmt 4703
Sfmt 4703
Avenue SE., Washington, DC, between 9
a.m. and 5 p.m., e.t., Monday through
Friday, except Federal holidays. The
FDMS is available 24 hours each day,
365 days each year. If you want
acknowledgment that we received your
comments, please include a selfaddressed, stamped envelope or
postcard or print the acknowledgement
page that appears after submitting
comments online.
Privacy Act: In accordance with 5
U.S.C. 553(c), DOT solicits comments
from the public to better inform its
rulemaking process. DOT posts these
comments, without edit, including any
personal information the commenter
provides, to https://www.regulations.gov
as described in the system records
notice (DOT/ALL–14 FDMS), which can
be reviewed at https://www.dot.gov/
privacy.
Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE., Room W64–
224, Washington, DC 20590–0001.
Office hours are 8:30 a.m. to 5 p.m., e.t.,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Services, telephone (202) 366–9826.
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
I. Background
Under 49 U.S.C. 31136(e) and 31315,
FMCSA may grant an exemption from
the FMCSRs for a two-year period if it
finds ‘‘such exemption would likely
achieve a level of safety that is
equivalent to or greater than the level
that would be achieved absent such
exemption.’’ The statute also allows the
Agency to renew exemptions at the end
of the two-year period.
The eight individuals listed in this
notice have requested an exemption
from the epilepsy prohibition in 49 CFR
391.41(b)(8). Accordingly, the Agency
will evaluate the qualifications of each
applicant to determine whether granting
the exemption will achieve the required
level of safety mandated by statute.
The physical qualification standard
for drivers regarding epilepsy found in
49 CFR 391.41(b)(8) states that a person
is physically qualified to drive a CMV
if that person:
Has no established medical history or
clinical diagnosis of epilepsy or any other
condition which is likely to cause the loss of
consciousness or any loss of ability to control
a CMV.
E:\FR\FM\16MRN1.SGM
16MRN1
Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
In addition to the regulations, FMCSA
has published advisory criteria 1 to
assist Medical Examiners in
determining whether drivers with
certain medical conditions are qualified
to operate a CMV in interstate
commerce. [49 CFR part 391,
APPENDIX A TO PART 391—MEDICAL
ADVISORY CRITERIA, section H.
Epilepsy: § 391.41(b)(8), paragraphs 3, 4,
and 5.]
The advisory criteria state the
following:
If an individual has had a sudden episode
of a non-epileptic seizure or loss of
consciousness of unknown cause that did not
require anti-seizure medication, the decision
whether that person’s condition is likely to
cause the loss of consciousness or loss of
ability to control a CMV should be made on
an individual basis by the Medical Examiner
in consultation with the treating physician.
Prior to considering certification, it is
suggested there be a six-month waiting
period from the time of the episode.
Following the waiting period, it is suggested
that the individual undergo a complete
neurological examination. If the results of the
examination are negative and anti-seizure
medication is not required, the driver may be
qualified.
In those individual cases where a driver
had a seizure or an episode of loss of
consciousness that resulted from a known
medical condition (e.g., drug reaction, high
temperature, acute infectious disease,
dehydration, or acute metabolic disturbance),
certification should be deferred until the
driver has recovered fully from that
condition, has no existing residual
complications, and is not taking anti-seizure
medication.
Drivers who have a history of epilepsy/
seizures, off anti-seizure medication and
seizure-free for 10 years, may be qualified to
operate a CMV in interstate commerce.
Interstate drivers who have had a single
unprovoked seizure may be qualified to drive
a CMV in interstate commerce if seizure-free
and off anti-seizure medication for five years
or more.
As a result of Medical Examiners
misinterpreting advisory criteria as
regulation, numerous drivers have been
prohibited from operating a CMV in
interstate commerce based on the fact that
they have had one or more seizures and are
taking anti-seizure medication, rather than an
individual analysis of their circumstances by
a qualified Medical Examiner based on the
physical qualification standards and medical
best practices.
On January 15, 2013, in a Notice of Final
Disposition entitled, ‘‘Qualification of
Drivers; Exemption Applications; Epilepsy
and Seizure Disorders,’’ (78 FR 3069),
FMCSA announced its decision to grant
requests from 22 individuals for exemptions
1 See https://www.ecfr.gov/cgi-bin/text-idx?SID=
e47b48a9ea42dd67d999246e23d97970&
mc=true&node=pt49.5.391&rgn=div5#ap49.5.391_
171.a and https://www.gpo.gov/fdsys/pkg/CFR2015-title49-vol5/pdf/CFR-2015-title49-vol5part391-appA.pdf.
VerDate Sep<11>2014
17:12 Mar 15, 2017
Jkt 241001
from the regulatory requirement that
interstate CMV drivers have ‘‘no established
medical history or clinical diagnosis of
epilepsy or any other condition which is
likely to cause loss of consciousness or any
loss of ability to control a CMV.’’ Since the
January 15, 2013 notice, the Agency has
published additional notices granting
requests from individuals for exemptions
from the regulatory requirement regarding
epilepsy found in 49 CFR 391.41(b)(8).
To be considered for an exemption from
the epilepsy prohibition in 49 CFR
391.41(b)(8), applicants must meet the
criteria in the 2007 recommendations of the
Agency’s Medical Expert Panel (MEP) (78 FR
3069).
II. Qualifications of Applicants
Brian Justin Brown
Mr. Brown is a 37 year-old class A
CDL holder in Pennsylvania. He has a
history of a seizure disorder and his last
seizure was October 2008. He takes antiseizure medication with the dosage and
frequency remaining the same since that
time. His physician states that he is
supportive of Mr. Brown receiving an
exemption.
Adam Cutler
Mr. Cutler is a 24 year-old driver in
Maine. He has a history of epilepsy and
his last seizure was in 2008. He takes
anti-seizure medication with the dosage
and frequency remaining the same since
that time. His physician states that he is
supportive of Mr. Cutler receiving an
exemption.
Rick L. Gardener
Mr. Gardener is a 58 year-old class A
CDL holder in Wisconsin. He has a
history of epilepsy and his last seizure
was in 2004. He takes anti-seizure
medication with the dosage and
frequency remaining the same since that
time. His physician states that he is
supportive of Mr. Gardener receiving an
exemption.
Nathan J. Hanson
Mr. Hanson is a 40 year-old driver in
Wisconsin. He has a history of a seizure
disorder and his last seizure was in
2006. He takes anti-seizure medication
with the dosage and frequency
remaining the same since 2013. His
physician states that he is supportive of
Mr. Hanson receiving an exemption.
Larry Henington
Mr. Henington is a 58 year-old driver
in Utah. He has a history of a seizure
disorder and his last seizure was in
2003. He takes anti-seizure medication
with the dosage and frequency
remaining the same since that time. His
physician states that he is supportive of
Mr. Henington receiving an exemption.
PO 00000
Frm 00133
Fmt 4703
Sfmt 4703
14105
Jason Speakman
Mr. Speakman is a 37 year-old driver
in Indiana. He has a history of a seizure
disorder and his last seizure was in
1999. He takes anti-seizure medication
with the dosage and frequency
remaining the same since that time. His
physician states that he is supportive of
Mr. Speakman receiving an exemption.
Robert Lee Sprouse Jr.
Mr. Sprouse is a 55 year-old driver in
Virginia. He has a history of a seizure
disorder and his last seizure was in
2003. He takes anti-seizure medication
with the dosage and frequency
remaining the same since 2014. His
physician states that he is supportive of
Mr. Sprouse receiving an exemption.
Aaron M. Witt
Mr. Witt is a 44 year-old driver in
Nebraska. He has a history of a seizure
disorder and his last seizure was in
1991. He takes anti-seizure medication
with the dosage and frequency
remaining the same since that time. His
physician states that he is supportive of
Mr. Witt receiving an exemption.
III. Request for Comments
In accordance with 49 U.S.C. 31136(e)
and 31315, FMCSA requests public
comment from all interested persons on
the exemption petitions described in
this notice. We will consider all
comments received before the close of
business on the closing date indicated
in the dates section of the notice.
IV. Submitting Comments
You may submit your comments and
material online or by fax, mail, or hand
delivery, but please use only one of
these means. FMCSA recommends that
you include your name and a mailing
address, an email address, or a phone
number in the body of your document
so that FMCSA can contact you if there
are questions regarding your
submission.
To submit your comment online, go to
https://www.regulations.gov and in the
search box insert the docket number
‘‘FMCSA–2016–0315’’ and click the
search button. When the new screen
appears, click on the blue ‘‘Comment
Now!’’ button on the right hand side of
the page. On the new page, enter
information required including the
specific section of this document to
which each comment applies, and
provide a reason for each suggestion or
recommendation. If you submit your
comments by mail or hand delivery,
submit them in an unbound format, no
larger than 81⁄2 by 11 inches, suitable for
copying and electronic filing. If you
submit comments by mail and would
E:\FR\FM\16MRN1.SGM
16MRN1
14106
Federal Register / Vol. 82, No. 50 / Thursday, March 16, 2017 / Notices
like to know that they reached the
facility, please enclose a stamped, selfaddressed postcard or envelope.
We will consider all comments and
materials received during the comment
period. FMCSA may issue a final
determination any time after the close of
the comment period.
V. Viewing Comments and Documents
To view comments, as well as any
documents mentioned in this preamble,
go to https://www.regulations.gov and in
the search box insert the docket number
FMCSA–2016–0315 and click ‘‘Search.’’
Next, click ‘‘Open Docket Folder’’ and
you will find all documents and
comments related to this notice.
Issued on: March 9, 2017.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2017–05256 Filed 3–15–17; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Pipeline and Hazardous Materials
Safety Administration
[Docket No. PHMSA–2016–0131]
Pipeline Safety: Deactivation of
Threats
Pipeline and Hazardous
Materials Safety Administration
(PHMSA), DOT.
ACTION: Notice; issuance of advisory
bulletin.
AGENCY:
PHMSA is issuing this
Advisory Bulletin to inform owners and
operators of gas transmission pipelines
that PHMSA has developed guidance on
threat identification and the minimum
criteria for deactivation of threats, as
established by a previously issued rule.
This Advisory Bulletin also provides
guidance to gas transmission pipeline
operators regarding documenting their
rationale of analyses, justifications,
determinations, and decisions related to
threat deactivation.
FOR FURTHER INFORMATION CONTACT:
Allan Beshore by phone at (816) 329–
3811 or email at allan.beshore@dot.gov.
All materials in this docket may be
accessed electronically at https://
www.regulations.gov. Information about
PHMSA may be found at https://
www.phmsa.dot.gov.
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
SUPPLEMENTARY INFORMATION:
I. Background
A critical element in an integrity
management (IM) program is the
identification of threats to pipeline
integrity. As required by section
VerDate Sep<11>2014
17:12 Mar 15, 2017
Jkt 241001
192.911(c), an IM program must contain
‘‘[a]n identification of threats to each
covered pipeline segment, which must
include data integration and a risk
assessment. An operator must use the
threat identification and risk assessment
to prioritize covered segments for
assessment (section 192.917) and to
evaluate the merits of additional
preventive measures and mitigative
measures (section 192.935) for each
covered segment.’’ Further requirements
detailed in section 192.921(a) state,
‘‘[a]n operator must select the
[assessment] method or methods best
suited to address the threats identified
to the covered segment.’’ The threats to
a particular pipeline segment dictate the
type of assessments the operator must
perform to fulfill the requirements of
section 192.921(a).
According to the Standard established
by the American Society of Mechanical
Engineers (ASME), ASME B31.8S–2004,
Section 2.2, an operator must consider
nine individual threat categories as part
of an IM program. As stated by ASME
B31.8S–2004, Section 5.10, an IM
program should provide criteria for
eliminating a threat from consideration
during a risk assessment; however, 49
CFR part 192—Subpart O does not
include provisions for the permanent
elimination of threats. An operator,
therefore, must continually consider all
threats in the evaluation of their IM
program through periodic reviews and
assessments, as required by section
192.937.
PHMSA acknowledges that threats
may be categorized as active, requiring
an integrity assessment, or inactive,
meaning that during a specific
assessment cycle the threat does not
trigger an integrity assessment, per
section 192.921(a). Operators, however,
must understand that threats to a
pipeline are not static, but vary over
time. Changes in threats can occur
suddenly, as in the case of catastrophic
outside forces like hurricanes,
earthquakes, or down-slope land
movements, or they can be gradual
changes, such as the introduction of
new wet-production gas sources into a
previously dry gas environment. Issues
may also develop into active threats
over time, such as coating degradation
that allows stress corrosion cracking or
external corrosion to develop. In other
cases, threats may become inactive over
time due to pipeline replacement
programs, the implementation of
effective preventative actions, or other
improvements to systems.
The periodic review required by
section 192.937 for a mature IM plan
must include the re-analysis of the nine
threat categories to determine status
PO 00000
Frm 00134
Fmt 4703
Sfmt 4703
changes for active or inactive threats.
An operator must continually monitor
operations and maintenance (O&M) and
other activities, integrating relevant
information during a threat analysis that
might indicate a change in the status of
a threat. Some operators inappropriately
label threats as inactive after they are
eliminated from consideration during
prior reviews and assessments, ignoring
the continuous supply of new
information provided during routine
O&M activities.
Some operators have opted to
eliminate threats from consideration
based on a lack of data, including
missing, incomplete, or unsubstantiated
data. Using insufficient data to
eliminate a threat is not technically
justified and is contrary to the guidance
in ASME B31.8S–2004, Appendices A1–
A9. Each of these appendices includes
language that states, ‘‘[w]here the
operator is missing data, conservative
assumptions shall be used when
performing the risk assessment or,
alternatively, the segment shall be
prioritized higher.’’ Additionally,
section 192.947(d) requires that
operators maintain, ‘‘[d]ocuments to
support any decision, analysis and
process developed and used to
implement and evaluate each element of
the baseline assessment plan and
integrity management program.’’ Section
192.947(d) further states, ‘‘[d]ocuments
include those developed and used in
support of any identification,
calculation, amendment, modification,
justification, deviation and
determination made, and any action
taken to implement and evaluate any of
the program elements.’’
PHMSA provides the following
guidance for determining the active or
inactive status of the nine threat
categories, with the understanding that
the status of a threat will change over
time:
Time-Dependent Threats
1. External Corrosion
For steel pipelines, the threat of
external corrosion may never be
eliminated.
2. Internal Corrosion
An operator should consider the past
operational history of the pipeline,
including, but not limited to: Upset
conditions, gas monitoring (including
partial-pressure analysis), bacterial
culture tests, flow direction and rates,
gas sources, solid and liquid analyses,
critical angles and liquid holdup points,
pigging and other cleaning history, the
presence of internal coatings, chemical
E:\FR\FM\16MRN1.SGM
16MRN1
Agencies
[Federal Register Volume 82, Number 50 (Thursday, March 16, 2017)]
[Notices]
[Pages 14104-14106]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05256]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2016-0315]
Qualification of Drivers; Exemption Applications; Epilepsy and
Seizure Disorders
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of applications for exemption; request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces receipt of applications from eight individuals
for an exemption from the prohibition in the Federal Motor Carrier
Safety Regulations (FMCSRs) against persons with a clinical diagnosis
of epilepsy or any other condition that is likely to cause a loss of
consciousness or any loss of ability to control a commercial motor
vehicle (CMV) to drive in interstate commerce. If granted, the
exemptions would enable these individuals who have had one or more
seizures and are taking anti-seizure medication to operate CMVs in
interstate commerce.
DATES: Comments must be received on or before April 17, 2017.
ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket No. FMCSA-2016-0315 using any of the
following methods:
Federal eRulemaking Portal: Go to https://www.regulations.gov. Follow the online instructions for submitting
comments.
Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE., West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m.,
e.t., Monday through Friday, except Federal Holidays.
Fax: 1-202-493-2251.
Instructions: Each submission must include the Agency name and the
docket number(s) for this notice. Note that all comments received will
be posted without change to https://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading below
for further information.
Docket: For access to the docket to read background documents or
comments, go to https://www.regulations.gov at any time or Room W12-140
on the ground level of the West Building, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday,
except Federal holidays. The FDMS is available 24 hours each day, 365
days each year. If you want acknowledgment that we received your
comments, please include a self-addressed, stamped envelope or postcard
or print the acknowledgement page that appears after submitting
comments online.
Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to https://www.regulations.gov as described in
the system records notice (DOT/ALL-14 FDMS), which can be reviewed at
https://www.dot.gov/privacy.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, (202) 366-4001, fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE., Room W64-224,
Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., e.t.,
Monday through Friday, except Federal holidays. If you have questions
regarding viewing or submitting material to the docket, contact Docket
Services, telephone (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Background
Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the FMCSRs for a two-year period if it finds ``such exemption
would likely achieve a level of safety that is equivalent to or greater
than the level that would be achieved absent such exemption.'' The
statute also allows the Agency to renew exemptions at the end of the
two-year period.
The eight individuals listed in this notice have requested an
exemption from the epilepsy prohibition in 49 CFR 391.41(b)(8).
Accordingly, the Agency will evaluate the qualifications of each
applicant to determine whether granting the exemption will achieve the
required level of safety mandated by statute.
The physical qualification standard for drivers regarding epilepsy
found in 49 CFR 391.41(b)(8) states that a person is physically
qualified to drive a CMV if that person:
Has no established medical history or clinical diagnosis of
epilepsy or any other condition which is likely to cause the loss of
consciousness or any loss of ability to control a CMV.
[[Page 14105]]
In addition to the regulations, FMCSA has published advisory
criteria \1\ to assist Medical Examiners in determining whether drivers
with certain medical conditions are qualified to operate a CMV in
interstate commerce. [49 CFR part 391, APPENDIX A TO PART 391--MEDICAL
ADVISORY CRITERIA, section H. Epilepsy: Sec. 391.41(b)(8), paragraphs
3, 4, and 5.]
---------------------------------------------------------------------------
\1\ See https://www.ecfr.gov/cgi-bin/text-idx?SID=e47b48a9ea42dd67d999246e23d97970&mc=true&node=pt49.5.391&rgn=div5#ap49.5.391_171.a and https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------
The advisory criteria state the following:
If an individual has had a sudden episode of a non-epileptic
seizure or loss of consciousness of unknown cause that did not
require anti-seizure medication, the decision whether that person's
condition is likely to cause the loss of consciousness or loss of
ability to control a CMV should be made on an individual basis by
the Medical Examiner in consultation with the treating physician.
Prior to considering certification, it is suggested there be a six-
month waiting period from the time of the episode. Following the
waiting period, it is suggested that the individual undergo a
complete neurological examination. If the results of the examination
are negative and anti-seizure medication is not required, the driver
may be qualified.
In those individual cases where a driver had a seizure or an
episode of loss of consciousness that resulted from a known medical
condition (e.g., drug reaction, high temperature, acute infectious
disease, dehydration, or acute metabolic disturbance), certification
should be deferred until the driver has recovered fully from that
condition, has no existing residual complications, and is not taking
anti-seizure medication.
Drivers who have a history of epilepsy/seizures, off anti-
seizure medication and seizure-free for 10 years, may be qualified
to operate a CMV in interstate commerce. Interstate drivers who have
had a single unprovoked seizure may be qualified to drive a CMV in
interstate commerce if seizure-free and off anti-seizure medication
for five years or more.
As a result of Medical Examiners misinterpreting advisory
criteria as regulation, numerous drivers have been prohibited from
operating a CMV in interstate commerce based on the fact that they
have had one or more seizures and are taking anti-seizure
medication, rather than an individual analysis of their
circumstances by a qualified Medical Examiner based on the physical
qualification standards and medical best practices.
On January 15, 2013, in a Notice of Final Disposition entitled,
``Qualification of Drivers; Exemption Applications; Epilepsy and
Seizure Disorders,'' (78 FR 3069), FMCSA announced its decision to
grant requests from 22 individuals for exemptions from the
regulatory requirement that interstate CMV drivers have ``no
established medical history or clinical diagnosis of epilepsy or any
other condition which is likely to cause loss of consciousness or
any loss of ability to control a CMV.'' Since the January 15, 2013
notice, the Agency has published additional notices granting
requests from individuals for exemptions from the regulatory
requirement regarding epilepsy found in 49 CFR 391.41(b)(8).
To be considered for an exemption from the epilepsy prohibition
in 49 CFR 391.41(b)(8), applicants must meet the criteria in the
2007 recommendations of the Agency's Medical Expert Panel (MEP) (78
FR 3069).
II. Qualifications of Applicants
Brian Justin Brown
Mr. Brown is a 37 year-old class A CDL holder in Pennsylvania. He
has a history of a seizure disorder and his last seizure was October
2008. He takes anti-seizure medication with the dosage and frequency
remaining the same since that time. His physician states that he is
supportive of Mr. Brown receiving an exemption.
Adam Cutler
Mr. Cutler is a 24 year-old driver in Maine. He has a history of
epilepsy and his last seizure was in 2008. He takes anti-seizure
medication with the dosage and frequency remaining the same since that
time. His physician states that he is supportive of Mr. Cutler
receiving an exemption.
Rick L. Gardener
Mr. Gardener is a 58 year-old class A CDL holder in Wisconsin. He
has a history of epilepsy and his last seizure was in 2004. He takes
anti-seizure medication with the dosage and frequency remaining the
same since that time. His physician states that he is supportive of Mr.
Gardener receiving an exemption.
Nathan J. Hanson
Mr. Hanson is a 40 year-old driver in Wisconsin. He has a history
of a seizure disorder and his last seizure was in 2006. He takes anti-
seizure medication with the dosage and frequency remaining the same
since 2013. His physician states that he is supportive of Mr. Hanson
receiving an exemption.
Larry Henington
Mr. Henington is a 58 year-old driver in Utah. He has a history of
a seizure disorder and his last seizure was in 2003. He takes anti-
seizure medication with the dosage and frequency remaining the same
since that time. His physician states that he is supportive of Mr.
Henington receiving an exemption.
Jason Speakman
Mr. Speakman is a 37 year-old driver in Indiana. He has a history
of a seizure disorder and his last seizure was in 1999. He takes anti-
seizure medication with the dosage and frequency remaining the same
since that time. His physician states that he is supportive of Mr.
Speakman receiving an exemption.
Robert Lee Sprouse Jr.
Mr. Sprouse is a 55 year-old driver in Virginia. He has a history
of a seizure disorder and his last seizure was in 2003. He takes anti-
seizure medication with the dosage and frequency remaining the same
since 2014. His physician states that he is supportive of Mr. Sprouse
receiving an exemption.
Aaron M. Witt
Mr. Witt is a 44 year-old driver in Nebraska. He has a history of a
seizure disorder and his last seizure was in 1991. He takes anti-
seizure medication with the dosage and frequency remaining the same
since that time. His physician states that he is supportive of Mr. Witt
receiving an exemption.
III. Request for Comments
In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated in the dates
section of the notice.
IV. Submitting Comments
You may submit your comments and material online or by fax, mail,
or hand delivery, but please use only one of these means. FMCSA
recommends that you include your name and a mailing address, an email
address, or a phone number in the body of your document so that FMCSA
can contact you if there are questions regarding your submission.
To submit your comment online, go to https://www.regulations.gov and
in the search box insert the docket number ``FMCSA-2016-0315'' and
click the search button. When the new screen appears, click on the blue
``Comment Now!'' button on the right hand side of the page. On the new
page, enter information required including the specific section of this
document to which each comment applies, and provide a reason for each
suggestion or recommendation. If you submit your comments by mail or
hand delivery, submit them in an unbound format, no larger than 8\1/2\
by 11 inches, suitable for copying and electronic filing. If you submit
comments by mail and would
[[Page 14106]]
like to know that they reached the facility, please enclose a stamped,
self-addressed postcard or envelope.
We will consider all comments and materials received during the
comment period. FMCSA may issue a final determination any time after
the close of the comment period.
V. Viewing Comments and Documents
To view comments, as well as any documents mentioned in this
preamble, go to https://www.regulations.gov and in the search box insert
the docket number FMCSA-2016-0315 and click ``Search.'' Next, click
``Open Docket Folder'' and you will find all documents and comments
related to this notice.
Issued on: March 9, 2017.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2017-05256 Filed 3-15-17; 8:45 am]
BILLING CODE 4910-EX-P